EUVIMEDEUVIMED entdecken
Crossref

Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial

Ana Julia Aguiar Freitas iD, Caroline Rocha Nunes, Max Senna Mano, Rhafaela Lima Causin, Stéphanie Calfa, Marco Antonio de Oliveira, Iara Viana Vidigal Santana, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques

Future Oncology · 2024

DOI: 10.2217/fon-2023-0886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Ana Julia Aguiar Freitas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Circulating MicroRNA, MicroRNAs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Department of Science and Technology - DECIT, Department of Science and Technology – DECIT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy is increasingly vital in monitoring neoadjuvant breast cancer treatment. This study collected plasma samples at three time points from participants in the Neoadjuvant Carboplatin in Triple Negative Breast Cancer (NACATRINE), analyzing miRNA expression with NanoString's nCounter® Human v3 miRNA assay. In the carboplatin arm, four ct-miRNAs exhibited dynamic changes linked to pathologic complete response, with a combined area under the curve of 0.811. Similarly, the non-carboplatin arm featured four ct-miRNAs with an area under the curve of 0.843. These findings underscore the potential of ct-miRNAs as personalized tools in breast cancer treatment, assisting in predicting treatment response and assessing the risk of relapse. Integrating ct-miRNA analysis into clinical practice can optimize decisions and enhance patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCirculating MicroRNAMicroRNAsHumansCarboplatinTranslational Research, BiomedicalNeoplasm Recurrence, LocalBiomarkersNeoadjuvant TherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

biomarkersliquid biopsyneoadjuvant chemotherapypathologic complete responsetriple-negative breast cancer

Substanzen

CarboplatinCirculating MicroRNAMicroRNAsBiomarkers

Autor:innen und Institutionen

  • Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
  • Grupo Oncoclínicas São Paulo, São Paulo, BR - 04538-132, Brazil.
  • Barretos Cancer Hospital, Nucleus of Epidemiology & Biostatistics Barretos, São Paulo, BR - 14784-400, Brazil.
  • Barretos Cancer Hospital, Pathology Department Barretos, São Paulo, BR - 14784-400, Brazil.
  • Barretos Cancer Hospital, Barretos, São Paulo, Brazil - 14784-400, Brazil.

ORCID-Profile: Ana Julia Aguiar Freitas

Förderung

  • Department of Science and Technology - DECIT
  • Department of Science and Technology – DECIT

Zitieren

APA

Aguiar Freitas, A. J., Nunes, C. R., Mano, M. S., Causin, R. L., Calfa, S., de Oliveira, M. A., Vidigal Santana, I. V., Pádua Souza, C., & Chiquitelli Marques, M. M. (2024). Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial. Future Oncology. https://doi.org/10.2217/fon-2023-0886

Vancouver

Aguiar Freitas AJ, Nunes CR, Mano MS, Causin RL, Calfa S, de Oliveira MA, et al. Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial. Future Oncology. 2024. doi:10.2217/fon-2023-0886

BibTeX
@article{AguiarFreitas2024,
  author = {Aguiar Freitas, Ana Julia and Nunes, Caroline Rocha and Mano, Max Senna and Causin, Rhafaela Lima and Calfa, Stéphanie and de Oliveira, Marco Antonio and Vidigal Santana, Iara Viana and Pádua Souza, Cristiano de and Chiquitelli Marques, Márcia Maria},
  title = {Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0886}
}
Kostenlos starten →